Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-25 @ 9:21 PM
NCT ID:
NCT02255656
Pre Assignment Details:
Subgroup analysis (\[Delayed Alemtuzumab Treatment\[DAT\] \& Immediate Alemtuzumab Treatment\[IAT\]subgroup) was performed only for outcome measures and safety analysis. Participants who rolled over from CAMMS223(NCT00050778) to CAMMS03409 (NCT00930553),then subsequently enrolled and took 24 mg alemtuzumab in CAMMS324 (NCT00548405) study, were not considered as part of DAT or IAT subgroup \& included in overall group only. Participant flow and Baseline analysis was performed on overall population only.
Recruitment Details:
The study was conducted at 142 study centers in 21 countries. A total of 1062 participants were screened between 7 January 2015 and 28 June 2016 and were enrolled in this current study (LPS13649 \[TOPAZ\]).
Study:
NCT02255656
Study Brief:
Results Section:
NCT02255656